EZH2 Mutation

CI-VAR-00002644Explore in graph →CIViC 163

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Follicular Lymphoma1
EZH2 Mutation	(prognostic)	Prognostic	B	Supports Better Outcome	4	accepted	EID1015 In advanced stage follicular lymphoma patients receiving rituximab + chemotherapy (R-CHOP or R-CVP), EZH2 mutations were associated with better failure free survival in patients with high-risk FLIPI s… (full text at CIViC) PMID 26256760 · Pastore et al., 2015 · Open in CIViC	civic
Malignant Neoplasm1
EZH2 Mutation OR SMARCA4 Loss OR SMARCB1 Loss	Tazemetostat	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11694 In this NCI-COG pediatric MATCH trial, 20 patients (aged 1-21 years) harboring tumors with EZH2 mutations or SMARCB1 or SMARCA4 loss were treated with tazemetostat. The most frequent tumor types were … (full text at CIViC) PMID ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Myelodysplastic Syndrome2
EZH2 Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID425 In myelodysplastic syndrome, patients with point mutations in EZH2 have worse overall survival that their wild-type counterparts. PMID 20601954 · Nikoloski et al., 2010 · Open in CIViC	civic
EZH2 Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	2	submitted	EID6945 In a study of 439 patients with myelodysplastic syndrome, patients with EZH2 mutations (N=10) has worse overall survival than wildtype patients (N=429) (P=0.02 univariate). This difference was also ob… (full text at CIViC) PMID 21714648 · Bejar et al., 2011 · Open in CIViC	civic